Cromoglicic acid (cromolyn) is regarded as a mast cell stabilising drug, although its exact mechanism of action appears to be much more complicated.
Recent reports suggest that cromolyn inhibits glycogen synthase kinase 3β and may therefore have potential to treat diabetes and obesity [2
] and may prove effective in treating insulin-induced lipoatrophy [3
]. It also has reported potential anti-fibrotic action through agonism of GPR35 [1
View more information in the IUPHAR Pharmacology Education Project: cromoglicic acid